Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study of evogliptin (DA-1229) for calcific aortic valve disease with mild-to-moderate aortic stenosis has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Stenosis
• Calcific Aortic Valve Disease

Drugs mentioned

• Evogliptin (evogliptin)

Snippet

Sponsor: REDNVIA Co., Ltd. | Conditions: Calcific Aortic Valve Disease | Phase 2, Phase 3 | Status: SUSPENDED